SARS‑CoV‑2: Review of Conditions Associated With Severe Disease and Mortality

Joshua Eyitemi, Britanie Thomas, Yazmin Ramos, Xue Feng, Chiamaka Ezekwesili


The 2019 Coronavirus Virus Disease (COVID‑19) represents a global public health challenge in the twenty‑first century. As of June 2020, the virus had spread across 216 countries across the globe. This paper aims to analyze and identify those existing comorbidities among COVID‑19 patients that represent potential risk factors for COVID‑19 complications, severe illness, and death. Multiple database resources were searched. The resources include the University of Saskatchewan library USearch, Google Scholar, PubMed, Medline, and the Google search engine. Thirty‑seven articles, which included 15 different types of chronic diseases, were selected. Among the reviewed diseases and conditions, cancer, diabetes, lymphopenia, hypertension, kidney disease, smoking, chronic obstructive pulmonary disease (COPD), and organ transplant were found to represent potential risk factors for COVID‑19 complications, severe illness, and death. Other conditions that require further research as to whether they predispose subjects to severe illness and death include coronary artery disease, cerebrovascular disease, valvular heart disease, gastrointestinal diseases, HIV/AIDS, asthma, and liver disease. In conclusion, this article explains the association between diseases mentioned above and the severity of COVID‑19 and clearly shows the population at risk. This paper will help government bodies and decision‑makers prioritize resources for these populations to reduce mortality rates and overall quality of life.


Chronic; COVID‑19; mortality

Full Text:



Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of

unknown etiology in Wuhan, China: The mystery and the

miracle. J Med Virol 2020;92:401‑2.

World Health Organization.Coronavirus disease

(COVID‑19) Situation Report – 51. Available from:‑source/coronaviruse/situationreports/20200311‑sitrep‑51‑covid‑19.pdf?sfvrsn=1ba62e57_10.

Xie J, Tong Z, Guan X, Du B, Qiu H. Clinical Characteristics

of Patients Who Died of Coronavirus Disease 2019 in China.

JAMA Netw Open 2020;3:e205619.

Wang C, Horby P, Hayden F, Gao G. A novel coronavirus

outbreak of global health concern. Lancet 2020;395:470‑3.

Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G,

van Goor H. Tissue distribution of ACE2 protein, the functional

receptor for SARS coronavirus. A first step in understanding

SARS pathogenesis. J Pathol 2004;203:631‑7.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course

and risk factors for mortality of adult inpatients with COVID‑19

in Wuhan, China: A retrospective cohort study. Lancet 2020;395:1054‑62.

Li JY, Duan XF, Wang LP, Xu YJ, Huang L, Zhang TF, et al.

Selective depletion of regulatory T cell subsets by docetaxel

treatment in patients with nonsmall cell lung cancer. J Immunol

Res 2014;2014:286170. doi: 10.1155/2014/286170.

Kamboj M, Sepkowitz K. Nosocomial infections in patients with

cancer. Lancet Oncol 2009;10:589‑97.

Longbottom ER, Torrance HD, Owen HC, Fragkou PC, Hinds CJ,

Pearse RM, et al. Features of postoperative immune suppression

are reversible with interferon gamma and independent of

interleukin‑6 pathways. Ann Surg 2016;264:370‑7.

Sica A, Massarotti M. Myeloid suppressor cells in cancer and

autoimmunity. J Autoimmun 2017;85:117‑25.

Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer

patients in SARS‑CoV‑2 infection: A nationwide analysis in

China. Lancet Oncol 2020;21:335‑7.

Al‑Quteimat OM, Amer AM. The impact of the COVID‑19

pandemic on cancer patients. Am J Clin Oncol 2020;43:452‑5.

Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al.

Kidney disease is associated with in‑hospital death of patients

with COVID‑19. Kidney Int 2020;97:829‑38.

Betjes MG. Immune cell dysfunction and inflammation in

end‑stage renal disease. Nat Rev Nephrol 2013;9:255‑65.

Cohen‑Hagai K, Rozenberg I, Korzets Z, Zitman‑Gal T,

Einbinder Y, Benchetrit S. Upper respiratory tract infection

among dialysis patients. Isr Med Assoc J 2016;18:557‑60.

Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M,

et al. Characteristics and outcomes of 21 critically Ill patients

with COVID‑19 in Washington State. JAMA 2020;323:1612‑4.

Berlin I, Thomas D, Le Faou AL, Cornuz J. COVID‑19 and

smoking. Nicotine Tob Res 2020;22:1650‑2.

Strzelak A, Ratajczak A, Adamiec A, Feleszko W. Tobacco

smoke induces and alters immune responses in the lung

triggering inflammation, allergy, asthma and other lung

diseases: A mechanistic review. Int J Environ Res Public Health

;15:1033. doi: 10.3390/ijerph 15051033.

Vardavas CI, Nikitara K. COVID‑19 and smoking: A systematic

review of the evidence. Tob Induc Dis 2020;18:20.

Cai H. Sex difference and smoking predisposition in patients

with COVID‑19. Lancet Respir Med 2020;8:e20.

Lippi G, Henry BM. Active smoking is not associated with

severity of coronavirus disease 2019 (COVID‑19). Eur J Intern

Med 2020;75:107‑8.

Arcavi L, Benowitz N. Cigarette smoking and infection. Arch

Intern Med 2004;164:2206‑16.

Lippi G, Henry BM. Chronic obstructive pulmonary disease is

associated with severe coronavirus disease 2019 (COVID‑19).

Respir Med 2020;167:105941. doi: 10.1016/j.rmed. 2020.105941.

Sahu KK, Jindal V, Siddiqui AD, Cerny J. Facing COVID‑19

in the hematopoietic cell transplant setting: A new challenge for

transplantation physicians. Blood Cells Mol Dis 2020;83:102439.

doi: 10.1016/j.bcmd. 2020.102439.

Huang J, Lin H, Wu Y, Fang Y, Kumar R, Chen G, et al.

COVID‑19 in posttransplant patients‑report of 2 cases. Am J

Transplant 2020;20:1879‑81.

Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic

manifestations of hospitalized patients with coronavirus disease

in Wuhan, China. JAMA Neurol 2020;77:683‑90.

Aggarwal G, Lippi G, Michael Henry B. Cerebrovascular disease

is associated with an increased disease severity in patients with

Coronavirus Disease 2019 (COVID‑19): A pooled analysis of

published literature. Int J Stroke 2020;15:385‑9.

Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical

course and outcomes of critically ill patients with SARS‑CoV‑2

pneumonia in Wuhan, China: A single‑centered, retrospective,

observational study. Lancet Respir Med 2020;8:475‑81.

Chu H, Zhou J, Wong BH, Li C, Chan JF, Cheng ZS, et al.

Middle East respiratory syndrome coronavirus efficiently infects

human primary T lymphocytes and activates the extrinsic and

intrinsic apoptosis pathways. J Infect Dis 2016;213:904‑14.

Zhang G, Hu C, Luo L, Fang F, Chen Y, Li J, et al. Clinical

features and short‑term outcomes of 221 patients with COVID‑19

in Wuhan, China. J Clin Virol 2020;127:104364. doi: 10.1016/j.

jcv. 2020.104364.

Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. reduction

and functional exhaustion of T cells in patients with coronavirus

disease 2019 (COVID‑19). Front Immunol 2020;11:827. doi:

3389/fimmu. 2020.00827.

Zheng YY, Ma YT, Zhang JY, Xie X. COVID‑19 and the

cardiovascular system. Nat Rev Cardiol 2020;17:259‑60.

Guo J, Huang Z, Lin L, Lv J. Coronavirus disease

(COVID‑19) and cardiovascular disease: A viewpoint

on the potential influence of angiotensin‑converting enzyme

inhibitors/angiotensin receptor blockers on onset and severity of

severe acute respiratory syndrome coronavirus 2 infection. J Am

Heart Assoc 2020;9:e016219.

Tan W, Aboulhosn J. The cardiovascular burden of coronavirus

disease 2019 (COVID‑19) with a focus on congenital heart

disease. Int J Cardiol 2020;309:70‑7.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical

characteristics of 138 hospitalized patients with 2019 novel

coronavirus‑infected pneumonia in Wuhan, China. JAMA


Demaria AN. Structural heart disease during a pandemic. Struct

Heart 2020;4:150‑1.

Wang B, Zhang L, Zhang D, Yuan H, Wu C, Zhang Y, et al.

Bedside ultrasound in assessment of 510 severe and critical

patients with COVID‑19 pneumonia in Wuhan, China. Adv

Ultrasound Diagn Ther 2020;4:60‑6.

Ilyas R, Wallis R, Soilleux EJ, Townsend P, Zehnder D,

Tan BK, et al. High glucose disrupts oligosaccharide recognition

function via competitive inhibition: A potential mechanism for

immune dysregulation in diabetes mellitus. Immunobiology


Geerlings SE, Hoepelman AI. Immune dysfunction in patients

with diabetes mellitus (DM). FEMS Immunol Med Microbiol


Bode B, Garrett V, Messler J, McFarland R, Crowe J, Booth R,

et al. Glycemic characteristics and clinical outcomes of

COVID‑19 patients hospitalized in the United States. J Diabetes

Sci Technol 2020;14:813‑82.

Roncon L, Zuin M, Rigatelli G, Zuliani G. Diabetic patients

with COVID‑19 infection are at higher risk of ICU admission

and poor short‑term outcome. J Clin Virol 2020;127:104354. doi:

1016/j.jcv. 2020.104354.

Richardson S, Hirsch JS, Narasimhan M, Crawford JM,

McGinn T, Davidson KW, et al. Presenting characteristics,

comorbidities, and outcomes among 5700 patients hospitalized

with COVID‑19 in the New York City area. JAMA


Singh AK, Gupta R, Misra A. Comorbidities in COVID‑19:

Outcomes in hypertensive cohort and controversies with

renin angiotensin system blockers. Diabetes Metab Syndr


Queiroz NSF, Barros LL, Azevedo MFC, Oba J, Sobrado CW,

Carlos AS, et al. Management of inflammatory bowel disease patients in the COVID‑19 pandemic era: A Brazilian tertiary

referral center guidance. Clinics (Sao Paulo) 2020;75:e1909.

Su J, Shen X, Ni Q, Zhao H, Cai J, Zhu B, et al. Infection of

severe acute respiratory syndrome coronavirus 2 in a patient with

AIDS. AIDS 2020;34:1575‑6.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of

lopinavir‑ritonavir in adults hospitalized with severe Covid‑19.

N Engl J Med 2020;382:1787‑99.

Yao TT, Qian JD, Zhu WY, Wang Y, Wang GQ. A systematic

review of lopinavir therapy for SARS coronavirus and MERS

coronavirus‑A possible reference for coronavirus disease‑19

treatment option. J Med Virol 2020;92:556‑63.

Blanco JL, Ambrosioni J, Garcia F, Martínez E, Soriano A,

Mallolas J, et al. COVID‑19 in patients with HIV: Clinical case

series. Lancet HIV 2020;7:e314‑6.

Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al.

A pneumonia outbreak associated with a new coronavirus of

probable bat origin. Nature 2020;579:270‑3.

Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time course

of lung changes at chest CT during recovery from coronavirus

disease 2019 (COVID‑19). Radiology 2020;295:715‑21.

Channappanavar R, Perlman S. Pathogenic human coronavirus

infections: Causes and consequences of cytokine storm and

immunopathology. Semin Immunopathol 2017;39:529‑39.

Bialek S, Boundy E, Bowen V, Chow N, Cohn A, et al.

Severe outcomes among patients with coronavirus disease

(COVID‑19) ‑ United States, February 12‑March 16, 2020.

MMWR Morb Mortal Wkly Rep 2020;69:343‑6.

Shiau S, Krause KD, Valera P, Swaminathan S, Halkitis PN. The

burden of COVID‑19 in people living with HIV: A syndemic

perspective. AIDS Behav 2020;24:2244‑9.

Rueda S, Mitra S, Chen S, Gogolishvili D, Globerman J,

Chambers L, et al. Examining the associations between

HIV‑related stigma and health outcomes in people living

with HIV/AIDS: A series of meta‑analyses. BMJ Open


Abrams E, ‘t Jong G, Yang C. Pediatric asthma and covid‑19.

Available from:


Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A,

et al. Clinical characteristics of Covid‑19 in New York city.

N Engl J Med 2020;382:2372‑4.

Rasmussen SA, Thompson LA. Coronavirus disease 2019 and

children: What pediatric health care clinicians need to know.

JAMA Pediatr 2020;174:743‑4.

Shaker MS, Oppenheimer J, Grayson M, Stukus D, Hartog N,

Hsieh EWY, et al. COVID‑19: Pandemic contingency planning

for the allergy and immunology clinic. J Allergy Clin Immunol

Pract 2020;8:1477‑88.e5.

CDC. (n.d). Coronavirus disease 2019 (covid‑19): People

with asthma. Available from:


Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al.

Epidemiological and clinical characteristics of 99 cases of 2019

novel coronavirus pneumonia in Wuhan, China: A descriptive

study. Lancet 2020;395:507‑13.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical

features of patients infected with 2019 novel coronavirus in

Wuhan, China. Lancet 2020;395:497‑506.

Lippi G, de Oliveira MHS, Henry BM. Chronic liver disease is

not associated with severity or mortality in Coronavirus disease

(COVID‑19): A pooled analysis. Eur J Gastroenterol

Hepatol 2021;33:114‑5.

Boettler T, Newsome PN, Mondelli MU, Maticic M, Cordero E,

Cornberg M, et al. Care of patients with liver disease during the

COVID‑19 pandemic: EASL‑ESCMID position paper. JHEP Rep

;2:100113. doi: 10.1016/j.jhepr. 2020.100113.

CDC. Coronavirus disease 2019 (COVID‑19). 2020.

Available from:‑ncov/


Government of Canada. People who are at high risk for severe

illness from covid‑19. 2020. Available from: https://www.canada.



WHO. Prevalence of tobacco smoking 2018. Available from: [Last accessed on 2022

Jun 20].

World Health Organization. (2020). Tobacco. World Health

Organization. from

detail/tobacco. [Last accessed on 2022 Jun 20].

WHO. Who statement: Tobacco use and covid‑19.

Available from:‑room/


Moujaess E, Kourie HR, Ghosn M. Cancer patients and research

during COVID‑19 pandemic: A systematic review of current

evidence. Crit Rev Oncol Hematol 2020;150:102972. doi:

1016/j.critrevonc. 2020.102972.

Gu J, Han B, Wang J. COVID‑19: Gastrointestinal manifestations

and potential fecal–oral transmission. Gastroenterology